Literature DB >> 20651747

The changing face of rheumatoid arthritis: sustained remission for all?

John D Isaacs1.   

Abstract

Earlier diagnosis and treatment, plus biological therapies, have transformed the outlook for many patients with rheumatoid arthritis. In the future, new biomarkers for diagnosis, prognosis and therapeutic response will further improve outcomes. Additionally, preclinical diagnosis and tolerogenic therapies could provide sustained remission for some individuals, although ethical and societal challenges must also be addressed before rheumatoid arthritis becomes 'yesterday's disease'.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20651747     DOI： 10.1038/nri2804

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


  61 in total

Review 1.  The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases.

Authors:  John A Hamilton; Paul P Tak
Journal:  Arthritis Rheum       Date:  2009-05

Review 2.  Osteoimmunology and the effects of the immune system on bone.

Authors:  Hiroshi Takayanagi
Journal:  Nat Rev Rheumatol       Date:  2009-11-03       Impact factor: 20.543

3.  Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.

Authors:  R F van Vollenhoven; S Ernestam; P Geborek; I F Petersson; L Cöster; E Waltbrand; A Zickert; J Theander; A Thörner; H Hellström; A Teleman; C Dackhammar; F Akre; K Forslind; L Ljung; R Oding; A Chatzidionysiou; M Wörnert; J Bratt
Journal:  Lancet       Date:  2009-08-08       Impact factor: 79.321

Review 4.  Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling.

Authors:  Antonio Manzo; Michele Bombardieri; Frances Humby; Costantino Pitzalis
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

5.  Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.

Authors:  S M van der Kooij; Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; M Güler-Yüksel; A H Zwinderman; P J S M Kerstens; P A H M van der Lubbe; W M de Beus; B A M Grillet; H K Ronday; T W J Huizinga; F C Breedveld; B A C Dijkmans; C F Allaart
Journal:  Ann Rheum Dis       Date:  2008-07-28       Impact factor: 19.103

6.  The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.

Authors:  Vappu Rantalaiho; Markku Korpela; Pekka Hannonen; Hannu Kautiainen; Salme Järvenpää; Marjatta Leirisalo-Repo; Markku Hakala; Kari Puolakka; Heikki Julkunen; Riitta Luosujärvi; Timo Möttönen
Journal:  Arthritis Rheum       Date:  2009-05

Review 7.  Cardiovascular morbidity and mortality in rheumatoid arthritis.

Authors:  Sherine E Gabriel
Journal:  Am J Med       Date:  2008-10       Impact factor: 4.965

8.  A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies.

Authors:  Mami Tamai; Atsushi Kawakami; Masataka Uetani; Shoichiro Takao; Kazuhiko Arima; Naoki Iwamoto; Keita Fujikawa; Toshiyuki Aramaki; Shin-Ya Kawashiri; Kunihiro Ichinose; Makoto Kamachi; Hideki Nakamura; Tomoki Origuchi; Hiroaki Ida; Kiyoshi Aoyagi; Katsumi Eguchi
Journal:  Arthritis Rheum       Date:  2009-06-15

9.  Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis.

Authors:  S ten Wolde; F C Breedveld; J Hermans; J P Vandenbroucke; M A van de Laar; H M Markusse; M Janssen; H R van den Brink; B A Dijkmans
Journal:  Lancet       Date:  1996-02-10       Impact factor: 79.321

10.  Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

Authors:  Paul Emery; Ferdinand C Breedveld; Stephen Hall; Patrick Durez; David J Chang; Deborah Robertson; Amitabh Singh; Ronald D Pedersen; Andrew S Koenig; Bruce Freundlich
Journal:  Lancet       Date:  2008-07-16       Impact factor: 79.321
View more
  31 in total

1.  [Biologics. Magic bullets - magic effects - magic costs? New therapeutics and their effects].

Authors:  O Frey; T Kamradt
Journal:  Ophthalmologe       Date:  2011-01       Impact factor: 1.059

2.  MiR-5571-3p and miR-135b-5p, derived from analyses of microRNA profile sequencing, correlate with increased disease risk and activity of rheumatoid arthritis.

Authors:  Cailong Liu; Axiao Pan; Xiaowei Chen; Jianxin Tu; Xiaoru Xia; Li Sun
Journal:  Clin Rheumatol       Date:  2019-02-01       Impact factor: 2.980

3.  Dynamic transcriptome analysis unveils key proresolving factors of chronic inflammatory arthritis.

Authors:  Jin-Sun Kong; Ji-Hwan Park; Seung-Ah Yoo; Ki-Myo Kim; Yeung-Jin Bae; Yune-Jung Park; Chul-Soo Cho; Daehee Hwang; Wan-Uk Kim
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

4.  TNF-β +252 A>G (rs909253) polymorphism is independently associated with presence of autoantibodies in rheumatoid arthritis patients.

Authors:  Fabiano Aparecido de Medeiros; Daniela Frizon Alfieri; Tatiana Mayumi Veiga Iriyoda; Neide Tomimura Costa; Elaine Regina Delicato de Almeida; Marcell Alysson Batisti Lozovoy; Naiara Lourenço Mari; Tamires Flauzino; Edna Maria Vissoci Reiche; Isaias Dichi; Andréa Name Colado Simão
Journal:  Clin Exp Med       Date:  2019-05-02       Impact factor: 3.984

Review 5.  Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?

Authors:  Gillian M Bell; Gary Reynolds; John D Isaacs
Journal:  Nat Rev Rheumatol       Date:  2011-08-02       Impact factor: 20.543

Review 6.  Chemokines in health and disease.

Authors:  Dayanidhi Raman; Tammy Sobolik-Delmaire; Ann Richmond
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

Review 7.  Investigational A₃ adenosine receptor targeting agents.

Authors:  Balázs Koscsó; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Expert Opin Investig Drugs       Date:  2011-04-02       Impact factor: 6.206

8.  Oral antigens induce rheumatoid arthritis-like inflammation in a rat model.

Authors:  Dandan Wu; Xiaoyu Liu; Hong Su; Xiao Chen; Huiyun Zhang; Dongsheng Hu; Zhong Huang; Ping-Chang Yang; Zhigang Liu
Journal:  Inflamm Res       Date:  2012-12-11       Impact factor: 4.575

9.  Analysis of lncRNA expression profiles by sequencing reveals that lnc-AL928768.3 and lnc-AC091493.1 are novel biomarkers for disease risk and activity of rheumatoid arthritis.

Authors:  Li Sun; Jianxin Tu; Cailong Liu; Axiao Pan; Xiaoru Xia; Xiaowei Chen
Journal:  Inflammopharmacology       Date:  2019-11-28       Impact factor: 4.473

10.  Phellinus baumii ethyl acetate extract alleviated collagen type II induced arthritis in DBA/1 mice.

Authors:  Taddesse Yayeh; Whi Min Lee; Dukhwan Ko; Seung-Choon Park; Jae Youl Cho; Hwa-Jin Park; In-Kyoung Lee; Seung-Hyung Kim; Seung-Bok Hong; Suk Kim; Bong-Sik Yun; Man Hee Rhee
Journal:  J Nat Med       Date:  2013-03-06       Impact factor: 2.343
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.